

LISTING OF CLAIMS:

Claims 1-40. (Cancelled).

Claim 41. (Previously Presented) An antibody molecule comprising

(a) a variable V_L -Region comprising complementary determining regions,

L-CDR1, L-CDR2, L-CDR3, wherein:

(1) L-CDR1 comprises SEQ ID NO: 143;

(2) L-CDR2 comprises SEQ ID NO: 144; and

(3) L-CDR3 comprises SEQ ID NO: 95; and

(b) a variable V_H -Region comprising complementary determining regions,

H-CDR1, H-CDR2, H-CDR3, wherein:

(1) H-CDR1 comprises SEQ ID NO: 146;

(2) H-CDR2 comprises SEQ ID NOs: 192; and

(3) H-CDR3 comprises SEQ ID NOs: 93.

Claim 42. (Previously Presented) The antibody molecule according to claim 41, wherein the antibody is of the IgG1 subtype.

Claim 43. (Previously Presented) The antibody molecule according to claim 41, wherein the variable V_H -region comprises SEQ ID NO: 89; and the variable V_L -region comprises SEQ ID NO: 91.

Claim 44. (Previously Presented) The antibody molecule according to claim 43, wherein the antibody is of the IgG1 subtype.

Claim 45. (Previously Presented) The antibody molecule according to claim 41, wherein the variable V_H -region comprises SEQ ID NO: 425; and the variable V_L -region comprises SEQ ID NO: 91.

Claim 46. (Previously Presented) The antibody molecule according to claim 45, wherein the antibody is of the IgG1 subtype.

Claim 47. (Previously Presented) A pharmaceutical composition comprising an antibody molecule according to claim 41 and a pharmaceutically acceptable carrier or diluent.

Claim 48. (Previously Presented) A pharmaceutical composition comprising an antibody molecule according to claim 44 and a pharmaceutically acceptable carrier or diluent.

Claim 49. (Previously Presented) A pharmaceutical composition comprising an antibody molecule according to claim 46 and a pharmaceutically acceptable carrier or diluent.